Long non-coding RNA (lncRNA) is an emerging therapeutic modality that may offer actionable novel targets in a variety of disease settings, and Eli Lilly and Company, already a leader in obesity and metabolic disease, is partnering with the Swiss biotech HAYA Therapeutics, SA in a multiyear discovery collaboration to find new therapeutic targets and preclinical candidates within the “dark genome.”
Key Takeaways
-
Focused on the dark genome and long non-coding RNA therapeutics, HAYA is partnering with Lilly to discover novel targets to address obesity and metabolic disease.
...
The two firms announced their collaboration, with an estimated total value of up to $1bn for HAYA, on 4 September. Just a week earlier, Bayer AG inked a licensing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?